Fibroblastic reticular cells (Harvard Medical School/Dana-Farber Cancer Institute/Massachusetts General Hospital)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameFibroblastic reticular cells (Harvard Medical School/Dana-Farber Cancer Institute/Massachusetts General Hospital)
Drug Alias NameFDCs (Harvard Medical School/Dana-Farber Cancer Institute/Massachusetts General Hospital)
ClassificationCell and gene therapy > Cell therapy
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsInflammationSepsis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesHarvard Medical School
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDana-Farber Cancer InstituteThe General Hospital Corporation D/B/A Massachusetts General HospitalHarvard Medical School
Active IndicationsN/A
Inactive IndicationsInflammationSepsis

Other Information

ATC CodeN/A
Related LinksN/A